73 results about "Advanced gastric cancer" patented technology

The invention belongs to the technical field of medicaments, and relates to TS-1 granules for treating advanced gastric cancer and a preparation method thereof. The method comprises the following steps of: preparing active medicaments tegafur, gimeracil and potassium oxonate into a cyclodextrin inclusion compound; and sieving the inclusion compound, uniformly mixing the sieved inclusion compound and pharmaceutically acceptable auxiliary materials and performing wet granulation or dry granulation to prepare the granules. The granules have the advantages of increasing the water solubility and stability of the medicaments, covering the bitter taste of the tegafur, prolonging the action time, improving the medication compliance of patients with cancer, greatly improving the bioavailability of the medicaments and reducing the toxic or side effect of the medicaments.

The invention discloses an anti-cancer medicinal composition, which comprises 15-70 parts by weight of plant polysaccharide and mainly comprises the following medicinal crops or mainly comprises a Chinese medicinal composition prepared by the following medicinal crops in parts by weight: 18-22 parts of astragalus, 13-17 parts of ginseng, 22-26 parts of angelica, 13-17 parts of honeysuckle and 13-17 parts of root of straight ladybell, wherein the plant polysaccharide is selected from one more of ganoderma lucidum polysaccharide, lentinan polysaccharide, cordyceps sinensis polysaccharide, coriolus versciclor polysaccharide, agaricus blazei polysaccharide, hericium erinaceus polysaccharide, maitake polysaccharide, ginkgo polysaccharide and ginseng polysaccharide. The invention also disclosesthe Chinese medicinal composition in the anti-cancer medicinal composition. The anti-cancer medicinal composition provided by the invention is used for treating advanced cancer in the case that surgery and concurrent chemoradiotherapy are unsuitable or invalid, particularly has an obvious treatment effect on the advanced gastric cancer; the total effectiveness ratio reaches about 90 percent; the total cure rate reaches about 30 percent; the three-year survival rate reaches about 40 percent; and the five-year survival rate reaches about 25 percent.

The present invention relates to a novel system for predicting a prognosis capable of predicting the prognosis of locally advanced gastric cancer, and more specifically, capable of predicting a clinical result after a resection during gastric cancer surgery through gene set enrichment comparative analysis.

The invention discloses a Chinese pharmaceutical composition for treating gastric cancer and osteocarcinoma, which is prepared from oldenlandia, barbat skullcap, house lizard, wasp's nest, pilose asiabell root, Chinese angelica root, job's tears, chicken's gizzard-skin, haw, scutellaria root, hairy vein agrimony, root of herbaceous peony and corydalis tuber through powdering and mixing homogeneously. The medicament can be prepared into powders or capsules.

The present invention relates to a novel system for predicting a prognosis capable of predicting the prognosis of locally advanced gastric cancer, and more specifically, capable of predicting a clinical result after a resection during gastric cancer surgery through gene set enrichment comparative analysis.

The present invention relates to a system for predicting a post-surgery prognosis or anticancer drug compatibility of advanced gastric cancer patients. An algorithm capable of predicting the prognosisand anticancer drug compatibility of advanced gastric cancer by using quantitative test results of the mRNA expression levels of a marker gene cluster and a reference gene cluster for the prognosis or anticancer drug compatibility thereof is developed so as to be usable as supplementary information for determining a treatment method for gastric cancer patients.

The invention discloses a traditional Chinese medicine for treating gastric cancer, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine is prepared from 12g of oldenlandia diffusa, 10g of the fruit of Chinese wolfberry, 10g of semen coicis, 9g of astragalus mongholicus, 9g of codonopsis pilosula, 8g of sculellaria barbata, 8g of angelica sinensis, 8g of radix paeoniae alba, 5g of endothelium corneum gigeriae galli, 5g of honeysuckle, 5g of pseudo-ginseng, 5g of fructus forsythia and 5g of frankincense. The traditional Chinese medicine has the following functions of nourishing liver and kidney, improving the production of body fluid and nourishing blood, invigorating stomach, helping to digest, prompting Qi circulation to relieve pain and clearing away heat and toxic materials and also plays roles in fighting bacterium and diminishing inflammation, draining pus and expelling toxin and removing swelling and lump on the basis of invigorating health effectively and immunity, and is capable of significantly inhibiting spread and transfer of cancer cells, reducing symptoms of patients with gastric carcinoma and prolonging the survival time of patients; in addition, the traditional Chinese medicine has no toxic and side effects so as to be especially beneficial for advanced gastric cancer patients.

The present invention relates to a humanized antibody binding to claudin 18.2 for treating cancer. The antibody does not bind to Claudin 18.1, but selectively binds to Claudin 18.2 to destroy tight connection between cells, so that the Claudin 18.2 cannot exert normal functions, and the antibody can be used for preventing or treating tumors, especially advanced gastric cancer.

The present invention discloses the nine biomarkers including HIF1A, FAM84B, CRIP2, GSN, RPL15, DLG1, MAT2A, PGBD2 and ID3 are respectively selected according to their specific and unique expression profile in the gastric cancer cells or gastric cancer tissue. Therefore, the nine biomarkers are related to diagnose gastric cancer, such as detecting early gastric cancer, staging gastric cancer, predicting prognosis of gastric cancer and diagnosing lymph node metastasis. By analyzing the expression value of at least one biomarker of a sample from a subject, the subject can be precisely diagnose the risk about gastric cancer.

The invention discloses a medicinal composition for treating late gastric cancer. The medicinal composition comprises the following raw materials in part by weight: 10 to 30 parts of ginseng, 50 to 150 parts of Yangtao actinidia root, 50 to 100 parts of glaucescent fissistigma root, 50 to 120 parts of loosestrife herb, 10 to 30 parts of bunge auriculate root, 10 to 20 parts of root of pseudo-ginseng, 10 to 30 parts of astragalus and 5 to 15 parts of dried ginger. The medicament has remarkable curative effect on the gastric cancer caused by various cancer cells, has low toxic or side effect, and is convenient to take.

The invention relates to a formula and a preparation method of a Hui nationality traditional Chinese medicinal Radix Astragali and Sonchus oleraceus L. root stomach cancer treatment pill. The pill is a green high-tech Chinese herbal medicine used for treating late stomach cancer, especially late stomach cancer which cannot be operated due to various reasons. The pill is a traditional Chinese medicinal pill prepared through the following steps: mixing of Radix Astragali, Radix Codonopsis, Sonchus oleraceus L. root, Cortex Acanthopanacis, Malaytea Scurfpea Fruit, Polygonatum sibiricum and other Chinese herbal medicines in proportion, water adding, decoction, extraction, concentration and pill preparation. The pill is mainly used for treating the stomach cancer, and also is used for treating the throat cancer, the esophagus cancer, the cardiac cancer, the colorectal cancer and other digestive system cancers. The pill has the characteristics of small medicine variety quantity and moderate dosage, and all the medicines are proved by modern medical science pharmacological experiments to be suitable for treating the cancers.

The invention discloses a late gastric cancer survival prediction method based on integrated learning, and the method comprises the steps: obtaining case data, and carrying out the data screening, and obtaining a data set; constructing a prediction model and training the prediction model based on the data set to obtain a completely trained prediction model; and evaluating the training complete prediction model based on the confusion matrix and the working curve. Aiming at the characteristic of imbalance of survival samples of advanced gastric cancer, the clinical prognosis model established by adopting an integrated learning technology can solve the problem of overfitting. The advanced gastric cancer survival prediction method based on ensemble learning can be widely applied to the field of medical data processing.

The invention provides a formula and preparation method of Hui-nationality traditional Chinese medicine aralia root bark granules for treating gastric cancer. The medicine is a green and high-tech traditional Chinese medicine for treating advanced gastric cancer, especially the advanced gastric cancer which cannot be subjected to a surgery due to various reasons. The Hui-nationality traditional Chinese medicine aralia root bark granules are traditional Chinese medicine granules prepared by mixing traditional Chinese medicines including aralia root bark, rhizoma curcumae, herba sarcandrae, fiveleaf akebia fruit, seaweed, cortex ailanthi, aloe and the like at a certain ratio, adding water and decocting, extracting, concentrating and granulating. The Hui-nationality traditional Chinese medicine aralia root bark granules are used for mainly treating the gastric cancer and can also be used for treating digestive system cancers including pharyngolaryngeal cancer, esophageal cancer, cardiac cancer, colorectal cancer and the like. The Hui-nationality traditional Chinese medicine aralia root bark granules have the characteristics of a few of medicines and moderate dosage; modern medicine pharmacological experiments of most of the selected medicines show that the medicines can be used for treating the cancer.

The invention provides a training method of a Faster RCNN (Recurrent Convolutional Neural Network) for enhancing automatic identification of a CT (Computed Tomography) image of gastric cancer. The training method comprises the following steps: acquiring a gastric cancer image in a progress stage; manually identifying the image; extracting a region of interest on the image by using a Faster RCNN network; preprocessing the images in the data set; performing standardization processing on the preprocessed image; dividing the standardized images into a training set and a test set; inputting the training set images into a network; verifying the training set through the test set; when the prediction effectiveness of the training set reaches a preset value, ending the training; and when the prediction effectiveness of the training set is lower than a preset value, reconstructing the training set for training. The Faster RCNN network trained by the method of the invention can identify the gastric cancer tumor in the progress stage of the enhanced CT image, and can perform T-stage processing on the gastric cancer tumor in the progress stage.

The present invention provides an antitumor agent comprising cisplatin and a combination drug of tegafur / gimeracil / oteracil potassium that ensures an excellent life-prolongation effect in advanced gastric cancer patients that is superior to that of the standard therapy in Europe and the U.S. using an agent that contains 5-FU and does not contain a dihydropyrimidine dehydrogenase inhibitor, by way of selecting the patients based on dihydropyrimidine dehydrogenase.

The invention discloses a HER2 negative advanced gastric cancer patient first-line chemotherapy curative effect prediction model based on VEGFA and application thereof, the model comprises a line chart used for evaluating chemotherapy curative effect, scores corresponding to four indexes BMI, Diagnose Pattern, VEGFA and CA19-9 in the first row from the second row to the fifth row are added to obtain a total score of a sixth row of patients, and the total score of the sixth row of patients is calculated to obtain the first-line chemotherapy curative effect prediction model based on the HER2 negative advanced gastric cancer patient first-line chemotherapy curative effect prediction model based on the HER2 negative advanced gastric cancer patient first-line chemotherapy curative effect. And correspondingly projecting the total score of the patient in the sixth row to the seventh row to obtain the probability that the treatment of the patient is invalid. The curative effect prediction line diagram integrating serum VEGFA and common baseline characteristics is simple, clear, popular and easy to understand, and clinical doctors and patients can conveniently perform operation to predict the curative effect. Meanwhile, a satisfactory prediction result is displayed by a curative effect line diagram, clinical judgment and layering can be better guided, and certain help is provided for treatment of HER2 negative advanced gastric cancer patients in the future.

The invention discloses a method for improving gastric cancer through TIL immune cells, which comprises the following steps of: firstly, cutting off tumors from the body of a patient, transporting tumor tissues to a GMP laboratory under sterile and cold-chain conditions, and separating to obtain initial tumor infiltrating lymphocytes; culturing the initial tumor infiltrating lymphocytes under proper conditions, amplifying by 10,000 times, further purifying, and then cryopreserving; resuscitating the tumor infiltrating lymphocytes, amplifying the tumor infiltrating lymphocytes to 8 * 10 < 7 >,and knocking down PD-1 by using a slow virus vector RNAi technology; further amplifying the number of the tumor infiltrating lymphocytes to 10 <10> or more; finally, infusing back the tumor infiltrating lymphocytes to the patient, and the average cell quantity of the tumor infiltrating lymphocytes injected each time is 7.3 * 10 < 8 >. The invention has efficient killing ability, can identify a plurality of antigen targets, uses autoimmune cells, and has no side effect, and the TIL immunotherapy can be used for patients with recurrent or metastatic advanced gastric cancer.

The invention specifically relates to nutritious food for people with gastric cancer and a preparation method thereof, belonging to the technical field of nutritious food. The nutritious food for people with gastric cancer contains nutritive elements consisting of protein, fat, carbohydrates, vitamins, mineral substances, amino acids, EPA, ginkgo flavonoids and nucleotide. Besides providing sufficient and comprehensive nutrients for the body, the nutritious food of the invention further enhances the barrier function of the gastric mucosa, better accords with metabolic physiological states, facilitates the protein synthesis and metabolic regulation of the body, promotes the recovery of gastric functions and morphology, prevents the translocation of bacteria and toxins and significantly reduces the incidence of stomach-derived infections; and the nutritious food is an effective means for improving the nutritional status of patients receiving chemotherapy. The nutritious food can improvethe nutritional status of chemotherapy patients with advanced gastric cancer, reduce the adverse reactions of the patients, and effectively improve the immunity of the patients.

The present invention discloses and claims methods and compositions for the treatment of platinum and / or taxane cancer treating agent-resistant / -refractory sub-populations and / or the mucinous adenocarcinoma sub-type of ovarian cancer subjects with the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2′-trimethylsilyl)ethyl]-20(S) camptothecin). The administration of Karenitecin by intravenous (i.v.) and / or oral methodologies are also disclosed and claimed. Karenitecin analogues, including but not limited to, Germanium-substituted Karenitecin, Deuterated Karenitecin, and “flipped” E-ring Karenitecin, are disclosed and claimed. In addition, Karenitecin and one or more cancer treating agents administered either concomitantly or in series via oral and / or i.v. means, are also disclosed and claimed. Methods for the administration of Karenitecin to: (i) increase Progression Free Survival (PFS); (ii) increase the platinum-free time interval; (iii) decrease CA-125 marker levels; and (iv) mitigate or prevent chemotherapeutic drug-resistance from developing are disclosed and claimed herein. Methods for the use of Karenitecin to treat advanced solid tumors; refractory or recurrent solid tumors; recurrent malignant glioma; primary malignant glioma; persistent or recurrent epithelial ovarian or primary peritoneal carcinoma; and other identified cancer types are also disclosed and claimed.

The invention belongs to the technical field of image recognition, and discloses a progress-stage gastric cancer edge state recognition system based on CT image omics features, and the system comprises a feature extraction network, a region generation network, and a target detection network. The feature extraction network is used for abstracting an input CT image with a drawn ROI and extracting animage omics feature; the region generation network selects an image omics feature by using a Pearson correlation analysis algorithm, establishes a Pearson correlation matrix, calculates paired imageomics feature correlation coefficients, selects an image omics feature with a maximum absolute correlation coefficient average value, and screens an optimal image omics feature by using an SFFS algorithm; the target detection network is used for predicting the positive probability of edge cutting. The system provided by the invention can identify microscopic medical image information which cannotbe identified by naked eyes, can accurately identify the infiltration depth of gastric cancer, and can pre-judge the preoperative excision state.

The invention provides a formula and preparation method of Hui-nationality traditional Chinese medicine rhizoma curcumae pills for treating gastric cancer. The medicine is a green and high-tech traditional Chinese medicine for treating advanced gastric cancer, especially the advanced gastric cancer which cannot be operated on due to various reasons. The Hui-nationality traditional Chinese medicine rhizoma curcumae pills are traditional Chinese medicine pills prepared by mixing traditional Chinese medicines including rhizoma curcumae, fiveleaf gynostemma herb, herba sarcandrae, radix linderae, herba pteridis multifidae, Chinese lobelia herb and the like at a certain ratio, adding water and decocting, extracting, concentrating and pilling. The Hui-nationality traditional Chinese medicine rhizoma curcumae pills are used for mainly treating the gastric cancer and can also be used for treating digestive system cancers including pharyngolaryngeal cancer, esophageal cancer, cardiac cancer, colorectal cancer and the like; the Hui-nationality traditional Chinese medicine rhizoma curcumae pills have the characteristics of a few of medicines and moderate dosage; modern medicine pharmacological experiments of most of the selected medicines show that the medicines can be used for treating the cancer.

The invention relates to a formula and a preparation method of a Hui nationality traditional Chinese medicinal three-seed component stomach cancer treatment granule. The granule is a green high-tech Chinese herbal medicine used for treating late stomach cancer, especially late stomach cancer which cannot be operated due to various reasons. The granule is a traditional Chinese medicinal granule prepared through the following steps: mixing of Concha Arcae, semen cuscutae, Airpotato Yam Rhizome, Salvia miltiorrhiza, root bark of Araiia chinensis L., Entada phaseoloides and other Chinese herbal medicines in proportion, water adding, decoction, extraction, concentration and granulation. The granule is mainly used for treating the stomach cancer, and also is used for treating the throat cancer, the esophagus cancer, the cardiac cancer, the colorectal cancer and other digestive system cancers. The granule has the characteristics of small medicine variety quantity and moderate dosage, and all the medicines are proved by modern medical science pharmacological experiments to be suitable for treating the cancers.

The invention provides a traditional Chinese medicine composition for removing toxins and dredging collaterals. The pharmaceutical active ingredient consists of the following components in parts by weight: 8 parts of radix astragali, 2 parts of poria cocos, 4 parts of rhizoma atractylodis macrocephalae, 4 parts of endothelium corneum gigeriae galli, 3 parts of radix ranunculi ternati, 1 part of gecko, 3 parts of fructus aurantii, 3 parts of dried orange peel and 1 part of liquorice. In the invention, the poria cocos and stir-fried rhizoma atractylodis macrocephalae have the functions of tonifying qi and invigorating the spleen; the radix astragali fried with honey promotes the functions of the poria cocos and stir-fried rhizoma atractylodis macrocephalae; the radix ranunculi ternati and gecko cooperate with each other and have the functions of clearing heat and removing toxins and resisting cancers and dredging collaterals; the fructus aurantii and dried orange peel can realize the functions of regulating qi movement, drying dampness, invigorating the stomach and resolving stasis while the endothelium corneum gigeriae galli has the functions of invigorating the spleen and harmonizing the stomach, and the three medicines regulate the qi movement of the whole body and keep normal rise and fall of the spleen-stomach qi from an overall perspective so as to realize the effects of improving body immunity and assisting in cancer resisting; and the liquorice has the functions of invigorating the spleen and replenishing qi and harmonizing the medicines in the formula. The medicines supplement each other to form a formula for invigorating the spleen, removing toxins and dredging collaterals, so that the progression of the advanced gastric cancer is effectively delayed, and the patient lifetime is prolonged.

The present invention discloses and claims methods and compositions for the treatment of subjects having advanced ovarian cancer, including platinum and / or taxane chemotherapy resistant or refractory sub-populations, with the administration to the subject having advanced ovarian cancer of the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2′-trimethylsilyl)ethyl]-20(S) camptothecin) in an amount sufficient to provide a therapeutic benefit. The administration of Karenitecin by intravenous (i.v.) and / or oral methodologies are also disclosed and claimed. Methods for the administration of Karenitecin to increase Progression Free Survival (PFS) are also disclosed and claimed herein.

The invention relates to a formula and a preparation method of Hui traditional Chinese medicine cyperus rotundus stomach cancer elimination particles. According to the present invention, the Hui traditional Chinese medicine cyperus rotundus stomach cancer elimination particles are the green high-tech Chinese herb for treating advanced stage stomach cancer, especially advanced stage stomach cancer incapable of being subjected to operation due to various causes; milkvetch root, codonopsis pilosula, salvia chinensis benth, seaweed, polygonatum sibiricum, cyperus rotundus, pteris multifida poir and other Chinese herbs are mixed according to a certain ratio, water is added, and decoction, extraction, concentration and granulation are performed to obtain the traditional Chinese medicine particles; and the Hui traditional Chinese medicine cyperus rotundus stomach cancer elimination particles mainly treat stomach cancer, can further treat throat cancer, esophageal cancer, cardiac cancer, large intestine cancer and other digestive system cancers, and have characteristics of less components and moderate doses, wherein the modern medical pharmacology experiment results prove that the selected medicines can treat cancers.

The invention relates to a formula and a preparation method of a Hui traditional Chinese medicine curcuma zedoaria stomach cancer recovery oral liquid. According to the present invention, the Hui traditional Chinese medicine curcuma zedoaria stomach cancer recovery oral liquid is the green high-tech Chinese herb for treating advanced stage stomach cancer, especially advanced stage stomach cancer incapable of being subjected to operation due to various causes; curcuma zedoaria, gynostemma pentaphyllum (thunb.) makino, sarcandra glabra, radix linderae, pteris multifida poir, lobelia chinensis lour and other Chinese herbs are mixed according to a certain ratio, water is added, and decoction, extraction and concentration are performed to obtain the traditional Chinese medicine oral liquid; and the Hui traditional Chinese medicine curcuma zedoaria stomach cancer recovery oral liquid mainly treats stomach cancer, can further treat throat cancer, esophageal cancer, cardiac cancer, large intestine cancer and other digestive system cancers, and has characteristics of less components and moderate doses, wherein the modern medical pharmacology experiment results prove that the selected medicines can treat cancers.

The invention discloses a formula of a Hui nationality traditional Chinese medicine taxus chinensis gastric cancer killing granule and a preparation method thereof. The granule belongs to a green high-tech Chinese herbal medicine for treating a late gastric cancer, particularly a late gastric cancer which is not treated because an operation cannot be performed due to various reasons. The granule belongs to a traditional Chinese medicine granule formed by mixing Chinese herbal medicines, such as taxus chinensis, rhizoma curcumae, radix actinidiae chinensis, herba andrographitis, cortex ailanthic and semen coicis according to a certain ratio, boiling with water, extracting, concentrating and granulating, mainly treats a gastric cancer, also treats digestive system cancers, such as a pharyngolaryngeal cancer, an esophagus cancer, a carcinoma of gastric cardia and a colorectal cancer, and has the characteristics that drugs are tasteless, the dosage is moderate, and most of selected drugs are proved, through modern medical pharmacological experiments, to be capable of treating cancers.

The invention provides a formula and preparation method of a Hui-nationality traditional Chinese medicine taxus chinensis bark oral solution for treating gastric cancer. The medicine is a green and high-tech traditional Chinese medicine for treating advanced gastric cancer, especially the advanced gastric cancer which cannot be subjected to a surgery due to various reasons. The Hui-nationality traditional Chinese medicine taxus chinensis bark oral solution is a traditional Chinese medicine oral solution prepared by mixing traditional Chinese medicines including taxus chinensis bark, rhizoma curcumae, radix actinidiae chinensis, herba andrographitis, cortex ailanthi, coix seed and the like at a certain ratio, adding water and decocting, extracting and concentrating. The Hui-nationality traditional Chinese medicine taxus chinensis bark oral solution is used for mainly treating the gastric cancer and can also be used for treating digestive system cancers including pharyngolaryngeal cancer, esophageal cancer, cardiac cancer, colorectal cancer and the like. The Hui-nationality traditional Chinese medicine taxus chinensis bark oral solution has the characteristics of a few of medicines and moderate dosage; modern medicine pharmacological experiments of most of the selected medicines show that the medicines can be used for treating the cancer.

The invention provides a formula and preparation method of Hui-nationality traditional Chinese medicine radix codonopsis and radix astragali seu hedysari granules for treating gastric cancer. The medicine is a green and high-tech traditional Chinese medicine for treating advanced gastric cancer, especially the advanced gastric cancer which cannot be subjected to a surgery due to various reasons. The Hui-nationality traditional Chinese medicine radix codonopsis and radix astragali seu hedysari granules are traditional Chinese medicine granules prepared by mixing traditional Chinese medicines including radix codonopsis, radix astragali seu hedysari, rhizoma coptidis, radix actinidiae chinensis, flos caryophyllata, radix gossypii hirsuti and the like at a certain ratio, adding water and decocting, extracting, concentrating and granulating. The Hui-nationality traditional Chinese medicine radix codonopsis and radix astragali seu hedysari granules are used for mainly treating the gastric cancer and can also be used for treating digestive system cancers including pharyngolaryngeal cancer, esophageal cancer, cardiac cancer, colorectal cancer and the like. The Hui-nationality traditional Chinese medicine radix codonopsis and radix astragali seu hedysari granules have the characteristics of a few of medicines and moderate dosage; modern medicine pharmacological experiments of most of the selected medicines show that the medicines can be used for treating the cancer.